US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Beta Bionic, Inc. (BBNX): IPO Is An "Execution Story" And in Growth Mode

Beta Bionic Inc (BBNX): Bullish IPO Roadshow Moves Underwriters to Amend Offering Size and Range

Beta Bionic Inc (BBNX): IPO Pops, Trades Strong on Opening Day

Beta Bionic, Inc. (BBNX) - Medical Device Company Targeting the Insulin Market Prepares for Q1 IPO

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Beta Bionic, Inc. set terms for an IPO that could raise up to $120 million</li>
<li>The IPO is led by Bank of America Securities and is scheduled to debut on Thursday, 1/30.</li>
<li>The company's product, iLet Bionic Pancreas, was approved by the FDA in May 2023 and posted $44.7 million in sales for the nine months ended September 30, 2024.  </li>
</ul>


Beta Bionic, Inc. set terms for an IPO that could raise up to $120 million
The IPO is led by Bank of America Securities and is scheduled to debut on Thursday, 1/30.
The company's product, iLet Bionic Pancreas, was approved by the FDA in May 2023 and posted $44.7 million in sales for the nine months ended September 30, 2024.  


Beta Bionic, Inc. (BBNX): IPO Terms Set for Medical Device Company Aiding Insulin Patients

Beta Bionics

Beta Bionic, Inc. (BBNX): IPO Terms Set for Medical Device Company Aiding Insulin Patients